A finished pharmaceutical product made with an active ingredient from HLB Pep has received marketing authorization from Mexico's pharmaceutical regulator, the Federal Commission for the Protection against Sanitary Risks (COFEPRIS).


Finished Drug Product Made with HLB Pep Ingredients Wins Marketing Approval in Mexico View original image

According to HLB Pep on November 10, the finished pharmaceutical product received domestic marketing authorization last year and has now received its first authorization from a foreign regulatory authority. HLB Pep has supplied leuprorelin active pharmaceutical ingredients (APIs) produced at its GMP facility since the domestic approval process began.


This year, Mexico's COFEPRIS recognized South Korea's Ministry of Food and Drug Safety (MFDS) as a reference regulatory authority. Medicines approved in South Korea can now qualify for authorization through a simplified review pathway that draws on the MFDS's assessment results. HLB Pep's ingredients, which have passed domestic GMP compliance assessments and have a drug master file (DMF) registration, were also accepted without a separate on-site inspection in Mexico.


Leuprorelin is a leading peptide hormone drug used to treat conditions including prostate cancer and precocious puberty. HLB Pep is one of the few peptide ingredient manufacturers in South Korea to have supplied leuprorelin APIs to domestic pharmaceutical companies since its predecessor, AnyGen, was in operation. Since joining the HLB Group last year, HLB Pep has upgraded its GMP facilities to cGMP standards and expanded its synthesis and purification equipment.


Building on this authorization, HLB Pep plans to expand overseas registrations for its peptide APIs, including leuprorelin, desmopressin, ganirelix and vasopressin. It is also proceeding in stages with the U.S. FDA DMF registration process.



HLB Pep CEO Sim Gyeongjae said, "This authorization means that the quality of our ingredients and our ability to respond to regulatory requirements have been validated by a foreign regulatory authority as well. Along with providing a stable supply of ingredients to support the global expansion of South Korean pharmaceutical companies, we will actively expand direct overseas supply of leuprorelin APIs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing